Rethinking the necessity of low glucose intervention for cerebral ischemia/reperfusion injury

来源 :中国神经再生研究(英文版) | 被引量 : 0次 | 上传用户:nihao99520
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Glucose is the essential and almost exclusive metabolic fuel for the brain. Ischemic stroke caused by a blockage in one or more cerebral arteries quickly leads to a lack of regional cerebral blood supply resulting in severe glucose deprivation with subsequent induction of cellular homeostasis disturbance and eventual neuronal death. To make up ischemia- mediated adenosine 5\'-triphosphate depletion, glucose in the ischemic penumbra area rapidly enters anaerobic metabolism to produce glycolytic adenosine 5\'-triphosphate for cell survival. It appears that an increase in glucose in the ischemic brain would exert favorable effects. This notion is supported by in vitro studies, but generally denied by most in vivo studies. Clinical studies to manage increased blood glucose levels after stroke also failed to show any benefits or even brought out harmful effects while elevated admission blood glucose concentrations frequently correlated with poor outcomes. Surprisingly, strict glycaemic control in clinical practice also failed to yield any beneficial outcome. These controversial results from glucose management studies during the past three decades remain a challenging question of whether glucose intervention is needed for ischemic stroke care. This review provides a brief overview of the roles of cerebral glucose under normal and ischemic conditions and the results of managing glucose levels in non-diabetic patients. Moreover, the relationship between blood glucose and cerebral glucose during the ischemia/reperfusion processes and the potential benefits of low glucose supplements for non-diabetic patients are discussed.
其他文献
随着真实世界研究、精准治疗等概念的提出和发展,科研工作者对医疗大数据处理的需求不断增大.机器学习技术因在处理海量、高维数据及开展预测研究等方面具有独特优势,故而近些年在医学领域的应用不断深入.除应用于疾病诊断、影像识别和风险预测外,越来越多的研究证明机器学习可被应用于临床药物治疗的决策支持相关研究中.本文就机器学习在临床药物治疗中的研究进展予以综述.
近年来,我国心血管疾病的患病率和死亡率呈明显上升趋势,心血管疾病已成为危害我国居民健康的主要疾病.间歇性禁食(IF)作为一种周期性能量限制的饮食干预方式,已被证明有广泛的健康益处,有助于减轻体质量、改善葡萄糖调节、降低血压和血脂水平、抑制炎性反应等,进而延缓心血管疾病的发生与发展.目前,我国学者对IF在防治心血管疾病中的潜在作用关注不足.本文通过对IF对血脂异常、肥胖、糖尿病、高血压等心血管疾病危险因素的影响及其机制进行综述,旨在为心血管疾病的防治提供新思路.本研究发现IF在心血管疾病防治中具有潜在的应用
阻塞性睡眠呼吸暂停低通气综合征(OSAHS)是以呼吸暂停、低通气、血氧饱和度下降及睡眠结构紊乱为特征的一种疾病,是心血管疾病的严重危险因素.近年来研究发现,OSAHS患者合并高血压、冠状动脉粥样硬化性心脏病、胰岛素抵抗、2型糖尿病、代谢综合征、非酒精性脂肪肝等疾病的发病率增加.诸多研究显示,OSAHS患者常存在明显的糖脂代谢紊乱,并在心血管疾病的发病率、死亡率中扮演着重要角色.因此,本文从OSAHS与糖脂代谢的关系入手,从病因学层面,就OSAHS引起糖脂代谢紊乱及胰岛素抵抗的机制作一综述,以期为临床治疗提
饮食干预是治疗肥胖的重要措施.间歇性禁食(IF)是一种正常能量和能量限制(或完全禁食)交替进行的膳食模式,主要类型包括隔日禁食、周期性禁食、限时禁食、斋月禁食等.现有研究表明,IF可通过多种机制改善肥胖及相关代谢紊乱,并促进健康.然而,何种IF方案对肥胖及相关代谢紊乱的干预效果更佳目前尚无定论.本文在介绍IF常见方案的基础上,针对IF在减轻体质量,改善血糖、血脂等方面发挥的作用及IF疗法的安全性进行综述,旨在为IF的深度推广、运用提供依据.本研究发现,IF不仅对减重有益,还有助于降低血糖和体脂,改善血脂谱
Hippocampus serves as a pivotal role in cognitive and emotional processes, as well as in the regulation of the hypothalamus-pituitary axis. It is known to undergo mild neurodegenerative changes during normal aging and severe atrophy in Alzheimer\'s dise
The role of neurotrophins in neuronal plasticity has recently become a strong focus inneuroregeneration research field to elucidate the biological mechanisms by which these molecules modulate synapses, modify the response to injury, and alter the adaptati
Taking advantage of the fast-growing knowledge of RNA-binding proteins (RBPs) we review the signature of downregulated genes for RBPs in the transcriptome of induced pluripotent stem cell neurons (iNeurons) modelling the neurodevelopmental Rubinstein Tayb
The onset and mechanisms underlying neurodegenerative diseases remain uncertain. The main features of neurodegenerative diseases have been related with cellular and molecular events like neuronal loss, mitochondrial dysfunction and aberrant accumulation o
The human brain contains an estimated 100 billion neurons that must be systematically organized into functional neural circuits for it to function properly.These circuits range from short-range local signaling networks between neighboring neurons to long-
Cognitive impairment caused by chemotherapy, referred to as “chemobrain,” is observed in approximately 70% of cancer survivors. However, it is not completely understood how chemotherapy induces cognitive dysfunction, and clinical treatment strategies for